文献速递遗传性与小管间质肾病

新型人源中和性PAPPA单克隆抗体治疗常染色体显性多囊肾病的临床前研究

Novel human neutralizing monoclonal antibodies against pregnancy-associated plasma protein A for the treatment of autosomal dominant polycystic kidney disease.
PubMed 文献 · Kidney Int · 2026-09-23

该研究开发了靶向PAPPA的人源中和性单克隆抗体,在体外阻断PAPPA对IGFBP2、4、5的切割,并在晚期和早期多囊肾病小鼠模型中验证疗效。结果显示抗体靶点结合良好,低剂量即可改善囊性病变、炎症和纤维化,但雌性小鼠的保护作用弱于雄性。

要点

  • 人源PAPPA单抗可阻断IGFBP2/4/5切割,在PKD小鼠中改善囊性病变、炎症和纤维化。
  • 低剂量PAPPA-mAb2(0.3 mg/kg/周)在雄性Pkd1RC/RC小鼠中即有效,提示长期安全性。
  • 雌性Pkd1RC/RC小鼠对PAPPA-mAb2的保护作用弱于雄性,临床试验设计需考虑性别差异。

核心结论

  • PAPPA单克隆抗体是治疗常染色体显性多囊肾病有前景的靶向疗法。
  • 新型人源PAPPA单抗靶点结合良好且低剂量有效,但疗效存在性别二态性。

研究设计与样本

  • 使用酵母表达平台生成人源PAPPA单抗,并在人上皮细胞中验证其中和PAPPA切割IGFBP2、4、5的能力。
  • 在晚期PKD雄性jck小鼠(6-12周龄)中腹腔注射PAPPA-mAb1(15或50 mg/kg/周)或PAPPA-mAb2(1、5或50 mg/kg/周)。
  • 在早期PKD雄性和雌性Pkd1RC/RC小鼠(4-16周龄)中腹腔注射PAPPA-mAb2(0.3、3或30 mg/kg/周)。

主要发现

  • PAPPA-mAb1和PAPPA-mAb2均阻断PAPPA介导的IGFBP2、4、5切割。
  • 在雄性jck小鼠中所有测试剂量均显示优异靶点结合,改善囊性病变、炎症和纤维化,并抑制IGF1Rβ及下游信号。
  • PAPPA-mAb2对雌性Pkd1RC/RC小鼠的保护作用弱于雄性。
  • 两种单抗在细胞系统和体内均优于Ansh Labs mAb。

关键数值与推荐

  • PAPPA-mAb1剂量为15或50 mg/kg/周,PAPPA-mAb2剂量为1、5或50 mg/kg/周(jck小鼠)。
  • PAPPA-mAb2剂量为0.3、3或30 mg/kg/周(Pkd1RC/RC小鼠)。
  • 细胞读出包括IGF1诱导的Akt磷酸化及全长和PAPPA切割的C端IGFBP4片段ELISA。

临床怎么用

  • PAPPA单抗可能成为ADPKD的靶向治疗选择,低剂量有效性支持长期用药安全性评估。
  • 临床试验设计需考虑性别差异对治疗反应的影响。

局限性

  • 研究仅在小鼠模型中进行,尚未在人体中验证。
  • 雌性小鼠疗效较弱的具体机制未完全阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Pregnancy-associated plasma protein A (PAPPA) cleaves insulin-like growth factor (IGF) binding proteins (IGFBP) 2, 4, and 5, releasing IGF1. PAPPA is overexpressed in polycystic kidneys, and its genetic elimination or suppression by mouse Ansh Labs PAPPA-mAb, which blocks IGFBP4 but not IGFBP5 cleavage, ameliorates polycystic kidney disease (PKD) in Pkd1RC/RC mice. Here, we sought to generate human pan-selective PAPPA-mAbs and test their efficacy in models of advanced and early PKD, using a wide range of doses in mice. METHODS: Yeast-based expression platforms were used to generate mAbs neutralizing PAPPA-mediated cleavage of IGFBP2, 4, and 5 in human epithelial cells (IGF1-induced Akt phosphorylation or ELISAs of full-length and PAPPA-cleaved C-terminal IGFBP4 fragments as readouts). Hydrogen-deuterium exchange (HDX) and cryo-EM were used to map PAPPA and mAb interacting sites. PAPPA-mAb1 (15 or 50 mg/kg/week) and PAPPA-mAb2 (1, 5, or 50 mg/kg/week) were administered intraperitoneally to male jck mice with advanced PKD from 6 to 12 weeks of age; PAPPA-mAb2 (0.3, 3, or 30 mg/kg/week) was administered to male and female Pkd1RC/RC mice with early PKD from 4 to 16 weeks of age. RESULTS: PAPPA-mAb1 and PAPPA-mAb2 blocked PAPPA-mediated cleavage of IGFBP2, 4, and 5. HDX and cryo-EM identified PAPPA regions interacting with IGFBP2, 4, and 5 protected by both PAPPA-mAbs. All doses administered to male mice equally demonstrated excellent target engagement and ameliorated cystic disease, inflammation, and fibrosis, and inhibited IGF1Rβ and downstream signaling. PAPPA-mAb2 protected female less than male Pkd1RC/RC mice. Both mAbs compared favorably with Ansh Labs mAb in cell systems and in vivo. CONCLUSIONS: Our study confirms that PAPPA-mAbs are a promising new targeted therapy for autosomal dominant PKD. Excellent target engagement and low-dose effectiveness of novel human PAPPA-mAbs, with implications for long-term safety, and sexual dimorphism of the therapeutic response should be considered in the design of clinical trials.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Hu E, Gardener MJ, Wang X, et al. Novel human neutralizing monoclonal antibodies against pregnancy-associated plasma protein A for the treatment of autosomal dominant polycystic kidney disease. Kidney Int. 2026. PMID: 42778146. doi:10.1016/j.kint.2026.08.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。